Respiratory System Drugs Practice Questions

Q: Which of the following antihistamines should be avoided in a truck driver with rhinitis?

Diphenhydramine. **Explanation:** The core concept tested here is the distinction between **First-generation** and **Second-generation** antihistamines (H1 blockers) regarding their ability to cross the blood-brain barrier (BBB). **Why Diphenhydramine is the Correct Answer:** Diphenhydramine is a **First-generation antihistamine**. These drugs are highly lipophilic and readily cross the BBB. Once in the CNS, they block H1 receptors involved in maintaining wakefulness, leading to significant **sedation**, psychomotor impairment, and decreased alertness. For a truck driver, this poses a severe safety risk (comparable to driving under the influence of alcohol). Therefore, it must be avoided. **Why the Other Options are Incorrect:** * **Fexofenadine & Desloratadine:** These are **Second-generation antihistamines**. They are more polar, have low lipid solubility, and are substrates for the P-glycoprotein efflux pump, meaning they do not cross the BBB in significant amounts. They are considered "non-sedating" and are the drugs of choice for individuals in safety-sensitive occupations. * **Astemizole:** This is also a second-generation antihistamine (though largely withdrawn globally due to cardiotoxicity/QT prolongation). Like others in its class, it does not cause significant sedation. **NEET-PG High-Yield Pearls:** * **Least Sedating:** Fexofenadine is often cited as the least sedating antihistamine because it has virtually zero CNS penetration even at high doses. * **First-generation side effects:** Aside from sedation, they cause significant **anticholinergic effects** (dry mouth, blurred vision, urinary retention). * **Metabolism:** Desloratadine is the active metabolite of Loratadine; Fexofenadine is the active metabolite of Terfenadine. * **Clinical Note:** Always advise patients that "non-sedating" antihistamines are preferred for pilots, drivers, and students.

Q: Which is the commonly used route of administration for Omalizumab in asthma?

Subcutaneous. **Explanation:** **Omalizumab** is a recombinant DNA-derived humanized monoclonal antibody used in the management of moderate-to-severe persistent allergic asthma. **1. Why Subcutaneous (Option A) is correct:** Omalizumab works by binding specifically to free **IgE** in the plasma, preventing it from binding to the high-affinity IgE receptors (FcεRI) on mast cells and basophils. Due to its proteinaceous nature (monoclonal antibody) and large molecular weight, it cannot be administered orally as it would be degraded by gastric enzymes. It is administered via the **subcutaneous (SC)** route, typically every 2 to 4 weeks, depending on the patient's body weight and serum IgE levels. **2. Why other options are incorrect:** * **Inhalational (Option B):** While most asthma drugs (like Salbutamol or Budesonide) are inhaled for local action, Omalizumab must reach the systemic circulation to neutralize circulating IgE. * **Intradermal (Option C):** This route is used for sensitivity testing (e.g., Mantoux test) but is not suitable for the volume or absorption kinetics required for monoclonal antibodies. * **Intramuscular (Option D):** SC is the preferred parenteral route for Omalizumab to ensure consistent, slow absorption and reduced injection site discomfort compared to IM. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Anti-IgE antibody; it reduces the "early phase" and "late phase" of the allergic response. * **Indication:** Step 5 of GINA guidelines for patients with high IgE levels not controlled by high-dose ICS + LABA. * **Black Box Warning:** Risk of **Anaphylaxis** (though rare, it can occur even after the first dose; patients must be monitored post-injection). * **Other Monoclonal Antibodies in Asthma:** Mepolizumab, Reslizumab, and Benralizumab (all target **IL-5** pathways for eosinophilic asthma).

Q: Which of the following does not have a role in the acute management of asthma?

Cromolyn sodium. The acute management of asthma focuses on rapid reversal of bronchoconstriction and reduction of airway inflammation. **Why Cromolyn Sodium is the correct answer:** Cromolyn sodium is a **Mast Cell Stabilizer**. It works by preventing the degranulation of mast cells and the subsequent release of inflammatory mediators (like histamine and leukotrienes). However, it has **no direct bronchodilatory action** and cannot reverse existing bronchospasm [3]. Therefore, it is used strictly for **prophylaxis** (preventing exercise-induced or allergen-induced asthma) and has no role in treating an acute attack. **Analysis of Incorrect Options:** * **Salbutamol:** A Short-Acting Beta-2 Agonist (SABA). It is the **drug of choice** for acute asthma due to its rapid onset of action in causing smooth muscle relaxation (bronchodilation) [2]. * **Ipratropium:** An Anticholinergic (SAMA). It blocks M3 receptors, reducing vagal tone and mucus secretion. It is used as an adjunct to SABAs in acute severe asthma (Status Asthmaticus). * **Steroids:** While they have a slow onset (4–6 hours), systemic steroids (e.g., Hydrocortisone or Prednisolone) are vital in acute management to reduce airway edema and prevent late-phase inflammatory responses [1]. **High-Yield NEET-PG Pearls:** * **Cromolyn Sodium:** Not absorbed orally (given via inhalation); main side effect is throat irritation/cough [3]. * **Drug of Choice for Acute Asthma:** Inhaled Salbutamol [2]. * **Drug of Choice for Chronic/Maintenance Asthma:** Inhaled Corticosteroids (ICS) like Fluticasone. * **Magnesium Sulfate:** Used intravenously in life-threatening asthma non-responsive to initial therapy.

Q: Which of the following statements regarding cromolyn sodium is FALSE?

It is effective in preventing exercise-induced asthma.. ### Explanation **Correct Answer: D. It is effective in preventing exercise-induced asthma.** **Note on the Question:** There appears to be a discrepancy in the provided key. In pharmacological reality, Cromolyn sodium **is** effective in preventing exercise-induced asthma. However, if this option is marked as "False" in a NEET-PG context, it is usually because Cromolyn is **not the drug of choice** (Short-acting beta-agonists are preferred) or because it must be taken *prophylactically* and cannot treat an ongoing attack. If the question implies Cromolyn is "ineffective," that statement is technically false, making it the correct choice for a "find the false statement" question. #### Why the other options are TRUE: * **Option A:** Cromolyn is a **mast cell stabilizer**, not a bronchodilator. It has no direct effect on bronchial smooth muscle tone and cannot reverse bronchoconstriction. * **Option B:** It works by inhibiting the degranulation of mast cells (by preventing the influx of calcium), thereby reducing the release of mediators like histamine and leukotrienes. * **Option C:** Cromolyn is generally considered safe and is approved for use across all age groups, including children, due to its minimal systemic absorption and low toxicity profile. #### NEET-PG High-Yield Pearls: * **Mechanism:** It inhibits "Cl- channels" in mast cells, preventing the calcium influx necessary for degranulation. * **Clinical Use:** It is strictly a **prophylactic** drug. It is used for bronchial asthma, allergic rhinitis, and allergic conjunctivitis. * **Route:** It is not absorbed orally; it is administered via inhalation (MDI/Spinhaler) or as nasal/ocular drops. * **Key Limitation:** It is useless in **acute asthma attacks** (Status Asthmaticus) because it cannot reverse existing airway obstruction.

Q: Which non-sympathomimetic bronchodilator is preferred in COPD?

Ipratropium bromide. **Explanation:** **1. Why Ipratropium Bromide is Correct:** In Chronic Obstructive Pulmonary Disease (COPD), the primary reversible component of airway obstruction is mediated by **vagal cholinergic tone**. [1], [2] Unlike asthma, where inflammation and bronchospasm are the main drivers, COPD patients have increased parasympathetic activity. **Ipratropium bromide**, a short-acting muscarinic antagonist (SAMA), blocks M3 receptors on bronchial smooth muscle, effectively inhibiting this cholinergic-induced bronchoconstriction. [2] It is often preferred over sympathomimetics in COPD because it provides a more sustained bronchodilatory effect and has a superior safety profile in elderly patients with cardiac comorbidities. **2. Why the Other Options are Incorrect:** * **Salmeterol (B):** This is a Long-Acting Beta-2 Agonist (LABA). While used in COPD maintenance, it is a **sympathomimetic** drug, which the question specifically excludes. [3] * **Terbutaline (C) & Salbutamol (D):** These are Short-Acting Beta-2 Agonists (SABA). They are **sympathomimetics** used for acute relief. While effective, they are not the "non-sympathomimetic" drug of choice. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Anticholinergics (like Tiotropium, a LAMA) are considered the first-line maintenance therapy for COPD. [3] * **Mechanism:** Ipratropium is a quaternary ammonium compound; it is poorly absorbed systemically, leading to minimal side effects (like dry mouth) and no significant CNS effects. * **Synergy:** Combining Ipratropium with Salbutamol (Combivent) provides a greater bronchodilatory effect than either drug alone in COPD. * **Asthma vs. COPD:** While Beta-2 agonists are the DOC for acute asthma, Anticholinergics are generally more effective in COPD. [1]

Q: Which beta-2 agonist bronchodilator is given by inhalation and is suitable for both terminating asthma attacks as well as for twice daily prophylaxis?

Formoterol. **Explanation:** The correct answer is **Formoterol**. This question tests the understanding of the pharmacokinetics of Beta-2 agonists, specifically the distinction between "onset of action" and "duration of action." **1. Why Formoterol is correct:** Formoterol is unique because it possesses both a **fast onset of action** (similar to Salbutamol) and a **long duration of action** (12 hours). * **Fast Onset:** Its moderate lipophilicity allows it to reach the receptor site quickly, making it suitable for "reliever" therapy to terminate acute asthma attacks. * **Long Duration:** It remains in the lipid bilayer of the airway membrane, providing sustained bronchodilation, making it suitable for "prophylaxis" (twice-daily dosing). This dual property is the basis for **SMART** (Single Maintenance and Reliever Therapy). **2. Why other options are incorrect:** * **Terbutaline:** A Short-Acting Beta-2 Agonist (SABA). While it has a fast onset for acute attacks, its duration is only 4–6 hours, making it unsuitable for twice-daily prophylaxis. * **Bambuterol:** A prodrug of terbutaline. It is an oral, ultra-long-acting agent. Because it is taken orally and requires metabolism, it has a slow onset and cannot be used to terminate an acute attack. * **Salmeterol:** A Long-Acting Beta-2 Agonist (LABA). Unlike Formoterol, it has a **slow onset of action** (15–30 minutes) due to high lipophilicity. Therefore, it is used for prophylaxis but *cannot* be used for acute relief. **High-Yield NEET-PG Pearls:** * **LABAs** should never be used as monotherapy in asthma; they must always be combined with an Inhaled Corticosteroid (ICS) to prevent mortality. * **Indacaterol** is an ultra-LABA (24-hour duration) used primarily for COPD. * **Salmeterol** has a "long side chain" that anchors it to the exosite of the receptor, explaining its long duration.

Q: What is the primary use of leukotriene antagonists in asthma management?

For prophylactic therapy in mild to moderate asthma.. Leukotriene receptor antagonists (LTRAs) like **Montelukast** and **Zafirlukast** work by blocking the CysLT1 receptor, preventing bronchoconstriction, airway edema, and mucus secretion induced by cysteinyl leukotrienes. ### Why Option C is Correct LTRAs are primarily used for **prophylaxis** and long-term maintenance of mild to moderate persistent asthma. They are particularly effective in specific phenotypes, such as **aspirin-induced asthma** (where leukotriene production is shunted) and **exercise-induced bronchoconstriction**. Because they are administered orally, they also improve compliance in pediatric patients. ### Why Other Options are Incorrect * **Option A:** While LTRAs can be "steroid-sparing," they are typically used as add-on therapy to Inhaled Corticosteroids (ICS), not as a replacement for them in conjunction with beta-agonists. ICS remain the first-line controller therapy. * **Option B:** Beta-blockers are generally contraindicated in asthma; LTRAs do not replace them. If the option meant "beta-agonists," LTRAs cannot replace them for acute symptom relief. * **Option C:** LTRAs have a slow onset of action and are **not effective** for reversing acute bronchospasm. Short-acting beta-agonists (SABA) like Salbutamol remain the drug of choice for acute attacks. ### High-Yield NEET-PG Pearls * **Mechanism:** Montelukast/Zafirlukast are CysLT1 antagonists; **Zileuton** is a 5-Lipoxygenase (5-LOX) inhibitor. * **Aspirin Triad (Samter’s Triad):** Asthma, Nasal polyps, and Aspirin sensitivity. LTRAs are the preferred treatment here. * **Side Effects:** Generally well-tolerated, but watch for **Churg-Strauss syndrome** (eosinophilic granulomatosis with polyangiitis) and neuropsychiatric effects (mood changes/suicidal ideation). * **Metabolism:** Zafirlukast inhibits CYP3A4 and CYP2C9, potentially increasing Warfarin levels.

Q: Tiotropium is contraindicated in:

Urinary retention. **Explanation:** **Tiotropium** is a long-acting muscarinic antagonist (LAMA) that works by blocking M3 receptors [3]. While it is primarily administered via inhalation for respiratory conditions, systemic absorption can occur, leading to typical anticholinergic side effects. **Why Urinary Retention is the Correct Answer:** The bladder's detrusor muscle is primarily under the control of **M3 receptors**, which mediate contraction to facilitate voiding. Antimuscarinic drugs like Tiotropium cause relaxation of the detrusor muscle and contraction of the urethral sphincter. In patients with pre-existing urinary outflow obstruction (e.g., Benign Prostatic Hyperplasia), this can precipitate **acute urinary retention** [2], [4]. Therefore, it is contraindicated or must be used with extreme caution in such patients. **Analysis of Incorrect Options:** * **A. Bronchial Asthma:** Tiotropium is actually an **indication** for asthma (especially as an add-on therapy in Step 4/5 management) due to its potent bronchodilatory effects [1]. * **B. Hypertension:** Unlike sympathomimetics (e.g., Salbutamol), anticholinergics do not significantly elevate blood pressure. Hypertension is not a contraindication. * **D. Peptic Ulcer Disease:** Anticholinergics reduce gastric acid secretion (via M1 blockade). While not a primary treatment today, they certainly do not worsen ulcers [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Tiotropium is "kinetic selective" for M3 receptors because it dissociates very slowly from M3 compared to M2 receptors, providing 24-hour bronchodilation [3]. * **Other Contraindications:** Use with caution in **Narrow-angle Glaucoma** (can increase intraocular pressure) [2]. * **Comparison:** Unlike Ipratropium (SAMA), which is short-acting and non-selective, Tiotropium is preferred for maintenance therapy in COPD [4].

Q: Which of the following mucolytics contains a free sulfhydryl group?

N-Acetylcysteine. **Explanation:** **N-Acetylcysteine (NAC)** is the correct answer because its chemical structure contains a **free sulfhydryl (-SH) group**. This group is central to its mechanism of action as a mucolytic: it directly reduces (breaks) the **disulfide bonds** in the mucoprotein matrix of sputum. By breaking these cross-links, NAC reduces the viscosity and elasticity of thick mucus, making it easier to expectorate. **Analysis of Incorrect Options:** * **Guanfacine (A):** This is a centrally acting alpha-2 adrenergic agonist used primarily in the treatment of ADHD and hypertension; it has no mucolytic properties. * **Amboxol (B):** A metabolite of Bromhexine, it acts as a **mucokinetic** and **mucosecretolytic**. It works by stimulating the production of surfactant and thinning secretions, but it does not possess a free sulfhydryl group to break disulfide bonds directly. * **Carbocisteine (C):** While derived from cysteine, the sulfhydryl group in Carbocisteine is **blocked (alkylated)**. Therefore, it does not act by breaking disulfide bonds in situ. Instead, it works by altering the synthesis of glycoproteins in the mucus-secreting cells (mucoregulatory action). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote Use:** Beyond its respiratory use, NAC is the specific antidote for **Paracetamol (Acetaminophen) poisoning** as it replenishes glutathione stores. * **Administration:** NAC can be administered via inhalation (nebulization) for respiratory conditions or orally/IV for toxicity. * **Adverse Effect:** When inhaled, NAC can trigger **bronchospasm**, especially in asthmatic patients; it is often co-administered with a bronchodilator. * **Renal Protection:** NAC is sometimes used to prevent **Contrast-Induced Nephropathy (CIN)** in high-risk patients.

Q: Olopatadine is:

Both a mast cell stabilizer and an anti-histamine. **Explanation:** **Olopatadine** is a second-generation antihistamine used primarily in the management of allergic conjunctivitis and allergic rhinitis. Its efficacy stems from a **dual mechanism of action**, making Option C the correct choice. 1. **Selective H1-Receptor Antagonism:** It acts as a potent and selective antagonist at H1 receptors, providing rapid relief from symptoms like itching and redness by blocking the effects of histamine already released in the tissues. 2. **Mast Cell Stabilization:** It inhibits the degranulation of mast cells, preventing the release of inflammatory mediators (histamine, leukotrienes, and prostaglandins) in response to allergens. This provides a long-term prophylactic effect. **Why other options are incorrect:** * **Option A & B:** While Olopatadine does possess these individual properties, selecting either one alone is incomplete. In the context of competitive exams like NEET-PG, when a drug exhibits multiple pharmacodynamic actions, the "dual action" or "both" option is the most accurate clinical description. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** It is most commonly used as **topical ophthalmic drops** (0.1% or 0.2%) or as a **nasal spray**. * **Advantages:** Unlike first-generation antihistamines, it has minimal systemic absorption when used topically, leading to a superior safety profile with negligible sedative or anticholinergic side effects. * **Other Dual-Action Agents:** Similar drugs often tested include **Ketotifen**, **Azelastine**, and **Epinastine**. * **Pure Mast Cell Stabilizers:** Contrast Olopatadine with **Sodium Cromoglycate** or **Nedocromil**, which are *only* mast cell stabilizers and lack direct antihistaminic activity.

Question 1

Which of the following antihistamines should be avoided in a truck driver with rhinitis?

Accepted Answer

Diphenhydramine

Answer

Astemizole

Answer

Desloratadine

Answer

Fexofenadine

Question 2

Which is the commonly used route of administration for Omalizumab in asthma?

Accepted Answer

Subcutaneous

Answer

Inhalational

Answer

Intradermal

Answer

Intramuscular

Question 3

Which of the following does not have a role in the acute management of asthma?

Accepted Answer

Cromolyn sodium

Answer

Ipratropium

Answer

Steroids

Answer

Salbutamol

Question 4

Which of the following statements regarding cromolyn sodium is FALSE?

Accepted Answer

It is effective in preventing exercise-induced asthma.

Answer

It does not relax bronchial smooth muscles.

Answer

It can reduce the release of histamine from mast cells.

Answer

It is approved for all ages.

Question 5

Which non-sympathomimetic bronchodilator is preferred in COPD?

Accepted Answer

Ipratropium bromide

Answer

Salmeterol

Answer

Terbutaline

Answer

Salbutamol

Question 6

Which beta-2 agonist bronchodilator is given by inhalation and is suitable for both terminating asthma attacks as well as for twice daily prophylaxis?

Accepted Answer

Formoterol

Answer

Terbutaline

Answer

Bambuterol

Answer

Salmeterol

Question 7

What is the primary use of leukotriene antagonists in asthma management?

Accepted Answer

For prophylactic therapy in mild to moderate asthma.

Answer

To be used in conjunction with beta-agonists to reduce the need for steroids.

Answer

As a sole therapy in place of beta-blockers.

Answer

As definitive therapy during an acute asthma attack.

Question 8

Tiotropium is contraindicated in:

Accepted Answer

Urinary retention

Answer

Bronchial asthma

Answer

Hypertension

Answer

Peptic ulcer disease

Question 9

Which of the following mucolytics contains a free sulfhydryl group?

Accepted Answer

N-Acetylcysteine

Answer

Guanfacine

Answer

Ambroxol

Answer

Carbocisteine

Question 10

Olopatadine is:

Accepted Answer

Both a mast cell stabilizer and an anti-histamine

Answer

A mast cell stabilizer

Answer

An anti-histamine

Answer

None of the above

Respiratory System Drugs — MCQs

Respiratory System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?